- Home
- PBBK vs UNCY Comparison
PBBK vs UNCY Comparison
Compare PBBK & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBBK
- UNCY
- Stock Information
- Founded
- PBBK 1919
- UNCY 2016
- Country
- PBBK United States
- UNCY United States
- Employees
- PBBK N/A
- UNCY N/A
- Industry
- PBBK Banks
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- PBBK Finance
- UNCY Health Care
- Exchange
- PBBK Nasdaq
- UNCY Nasdaq
- Market Cap
- PBBK 35.9M
- UNCY 31.9M
- IPO Year
- PBBK N/A
- UNCY 2021
- Fundamental
- Price
- PBBK $14.11
- UNCY $0.53
- Analyst Decision
- PBBK
- UNCY Strong Buy
- Analyst Count
- PBBK 0
- UNCY 4
- Target Price
- PBBK N/A
- UNCY $5.50
- AVG Volume (30 Days)
- PBBK 1.3K
- UNCY 1.9M
- Earning Date
- PBBK 11-13-2024
- UNCY 11-13-2024
- Dividend Yield
- PBBK N/A
- UNCY N/A
- EPS Growth
- PBBK N/A
- UNCY N/A
- EPS
- PBBK 0.64
- UNCY N/A
- Revenue
- PBBK $11,875,000.00
- UNCY N/A
- Revenue This Year
- PBBK N/A
- UNCY N/A
- Revenue Next Year
- PBBK N/A
- UNCY N/A
- P/E Ratio
- PBBK $22.20
- UNCY N/A
- Revenue Growth
- PBBK N/A
- UNCY N/A
- 52 Week Low
- PBBK $11.71
- UNCY $0.20
- 52 Week High
- PBBK $17.50
- UNCY $1.82
- Technical
- Relative Strength Index (RSI)
- PBBK 26.10
- UNCY 58.51
- Support Level
- PBBK $14.10
- UNCY $0.41
- Resistance Level
- PBBK $15.12
- UNCY $0.55
- Average True Range (ATR)
- PBBK 0.10
- UNCY 0.06
- MACD
- PBBK -0.06
- UNCY -0.00
- Stochastic Oscillator
- PBBK 0.98
- UNCY 58.06
About PBBK PB Bankshares Inc.
PB Bankshares Inc follows a community bank model and provides multiple services to individuals and small to midsize businesses. Its business consists of attracting retail and commercial deposits from the general public in its market area and investing those deposits, together with funds generated from operations and borrowings, in commercial real estate loans, commercial and industrial loans, construction, home equity lines of credit and to a lesser extent, one- to four-family residential real estate loans and consumer loans.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.